What is the difference between
Real-World Data (RWD) and
Real-World Evidence (RWE)?

What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)?

Real-world data and real-world evidence are related terms used in the field of healthcare and clinical research. While they share some similarities, they have distinct meanings and applications:

  • Real-World Data (RWD): RWD refers to data collected from various sources outside of traditional clinical trial settings. It includes information derived from electronic health records (EHRs), claims and billing databases, registries, wearable devices, mobile apps, and other healthcare systems. RWD can encompass a wide range of data types, such as patient demographics, medical history, laboratory results, treatment patterns, and health outcomes.
  • Real-World Evidence (RWE): RWE is the analysis and interpretation of real-world data to generate evidence about the usage, safety, effectiveness, and value of medical interventions (drugs, devices, procedures) in real-world settings. RWE provides insights into how treatments perform and how they affect patient outcomes and healthcare systems. It helps complement the evidence generated from randomized controlled trials (RCTs), which are conducted under controlled conditions.

In summary, RWD refers to the raw data collected from real-world sources, while RWE is the evidence generated from analyzing and interpreting that data. RWE helps bridge the gap between controlled clinical trial settings and real-world clinical practice, providing valuable insights into the effectiveness and safety of healthcare interventions in diverse patient populations and settings.

How do pharmaceutical companies use Real World Data?

Pharmaceutical companies use real-world data (RWD) in several ways to inform various aspects of their drug development and commercialization processes. Here are some common applications of RWD in the pharmaceutical industry:

  1. Observational Studies: Pharmaceutical companies may conduct observational studies using RWD to gather evidence on the safety, efficacy, and real-world outcomes of their drugs. These studies can provide insights into patient populations, treatment patterns, adherence, and long-term effects, among other factors.
  2. Post-Marketing Surveillance: Once a drug is approved and available in the market, pharmaceutical companies rely on RWD to monitor its safety and detect potential adverse events. They may analyze RWD from sources like adverse event reporting systems, electronic health records, and health insurance claims to identify any safety signals or patterns.
  3. Comparative Effectiveness Research (CER): RWD enables pharmaceutical companies to conduct comparative effectiveness research, comparing their drugs against existing treatments or competitors. By leveraging RWD, they can assess how their drugs perform in real-world settings, analyze treatment outcomes, and identify potential areas for improvement or differentiation.
  4. Health Economics and Outcomes Research (HEOR): Pharmaceutical companies utilize RWD to conduct health economics and outcomes research. This involves assessing the economic impact and cost-effectiveness of their drugs, analyzing real-world treatment costs, resource utilization, and patient outcomes to demonstrate the value proposition of their products.
  5. Market Research and Targeting: RWD plays a crucial role in market research and targeting efforts by pharmaceutical companies. They can analyze RWD to understand disease prevalence, patient demographics, and treatment patterns, helping them identify target patient populations, optimize marketing strategies, and refine their product positioning.
  6. Regulatory Submissions: RWD may also be used in regulatory submissions to support post-approval commitments, label expansions, or safety updates. By providing robust real-world evidence, pharmaceutical companies can enhance the regulatory understanding of their drugs and potentially influence regulatory decisions.

It’s worth noting that the use of RWD by pharmaceutical companies must adhere to strict privacy and data protection regulations, ensuring patient confidentiality and maintaining data integrity throughout the process.

How do researchers obtain Real-World Data?

Obtaining real-world data (RWD) involves accessing and collecting data from various sources outside of controlled clinical trial settings. Here are some common methods to obtain RWD:

  1. Electronic Health Records (EHRs): EHRs contain patient-level data captured during routine clinical care. Depending on the healthcare system or organization, researchers may be able to request access to de-identified or anonymized EHR data for research purposes. Collaboration with healthcare providers or institutions is often required to obtain access to EHR data.
  2. Claims and Billing Databases: Claims and billing databases, maintained by insurance companies or government agencies, contain information on healthcare services, procedures, prescriptions, and patient demographics. Researchers can often obtain access to de-identified or anonymized claims data for analysis.
  3. Registries and Disease-Specific Databases: Disease registries, such as cancer registries, cardiovascular registries, or rare disease registries, collect data on specific conditions or patient populations. Researchers can collaborate with registry owners or participate in existing research networks to gain access to registry data.
  4. Patient-Reported Outcomes (PROs): PRO data is collected directly from patients, usually through surveys or questionnaires, to capture their perspectives on symptoms, quality of life, treatment satisfaction, and other outcomes. Researchers can design studies and collect PRO data directly from patients or collaborate with patient advocacy groups.
  5. Wearable Devices and Mobile Apps: With the increasing use of wearable devices and health-related mobile apps, researchers can collect real-time data on patient activity levels, vital signs, sleep patterns, and other health metrics. Collaboration with device manufacturers or app developers may be necessary to obtain access to such data.
  6. Health System Partnerships: Establishing partnerships with healthcare systems, hospitals, or clinics can provide researchers with access to a wealth of RWD. Collaborative research agreements can be set up to access and analyze data from these systems while ensuring patient privacy and data security.
  7. Publicly Available Datasets: Some RWD sources, such as government databases or public health agencies, provide openly accessible datasets for research purposes. Examples include population health surveys, disease surveillance systems, or health statistics published by regulatory authorities.

 

The author generated this text in part with ChatGPT, OpenAI’s large-scale language-generation model. Upon generating draft language, the author reviewed, edited, and revised the language to their own liking and takes ultimate responsibility for the content of this publication.

The right insights can help you drive access for your brand

Look through our white papers, case studies and other resources to find out how our research drives innovation and results.